ReiThera’s COVID-19 vaccine looks to Phase 3 trial after preliminary Phase 2 data

Antibody responses against the SARS-CoV-2 spike protein were found in 99% of volunteers after the second dose of ReiTheraâs COVID-19 vaccine candidate, according to Phase 2 preliminary data.